Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthstream (HSTM) Research & Development (2016 - 2025)

Healthstream (HSTM) has disclosed Research & Development for 16 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 16.35% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.0 million through Dec 2025, up 4.28% year-over-year, with the annual reading at $51.0 million for FY2025, 4.28% up from the prior year.
  • Research & Development for Q4 2025 was $14.8 million at Healthstream, up from $12.1 million in the prior quarter.
  • The five-year high for Research & Development was $14.8 million in Q4 2025, with the low at $9.5 million in Q1 2021.
  • Average Research & Development over 5 years is $11.6 million, with a median of $11.7 million recorded in 2022.
  • The sharpest move saw Research & Development soared 32.01% in 2021, then dropped 5.01% in 2023.
  • Over 5 years, Research & Development stood at $11.5 million in 2021, then rose by 3.08% to $11.8 million in 2022, then increased by 1.04% to $11.9 million in 2023, then rose by 6.3% to $12.7 million in 2024, then grew by 16.35% to $14.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $14.8 million, $12.1 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.